Collegium Pharmaceuticals Inc., a company that specializes in
pharmaceuticals and focuses on the development of products that integrates its
DETERx technology for the treatment of chronic pain and diseases, has announced
that an independent review of Xtampza ER will be published in The Journal of the American Medical Association
(JAMA).
The review, which was previously published by The Medical Letter, is titled “A New Abused-Deterrent
Opioid-Xtaampza ER.”
JAMA is one of the
most renowned and most read medical journals worldwide. The Medical Letter has been praised on a large scale for its
unbiased information when discussing drug therapy. The two publications
collaborate each month to choose one article to be printed in both journals.
The article can be read at http://jama.jamanetwork.com/article.aspx?articleid=2547752.
Journal of the American Medical Association to publish Xtampza ER review
Alerts Sign-up